Dataset Information

Molecular characterisation and epidemiology of transmission of intraoperative Staphylococcus aureus isolates stratified by vancomycin minimum inhibitory concentration (MIC).

ABSTRACT:

Background

Reduced vancomycin susceptibility in Staphylococcus aureus (S. aureus) is considered a more pathogenic strain characteristic and is associated with treatment failure. We aimed to characterise the epidemiology of intraoperative transmission of S. aureus isolates with reduced vancomycin susceptibility.

Methods

S. aureus isolates (N=173) collected from 274 randomly selected operating room environments at three major academic medical centres in 2009-2010 were characterised by vancomycin minimum inhibitory concentration (MIC). We aimed to characterise the transmission dynamics for VISA and isolates with relatively reduced vancomycin (MIC= 2μg/mL) susceptibility at the range of therapeutic differentiation.

Results

Intraoperative S. aureus MIC was 1.38 ± 0.34 μg/mL. No VISA isolates were identified (95% upper confidence limit 2.1%) and those with an MIC of 2 μg/mL accounted for 12.72% (22/173) of all isolates. MIC=2 μg/mL isolates were more frequently cultured from the hands of healthcare providers [19.3% (16/83)] versus otherwise [6.7% (6/90)], with unadjusted risk ratio 2.89, P=0.021, and from patients with >2 major comorbidities [25.0% (8/32)] versus otherwise [9.9% (14/141)], with unadjusted risk ratio 2.52, P=0.035. Both were significant when tested simultaneously. The adjusted relative risk for provider hands was 2.77 (95% CI 1.15 to 6.69, P=0.024). The adjusted relative risk for patients with >2 major comorbidities was 2.37 (95% CI 1.11 to 5.05, P=0.026). MIC=2μg/mL was not associated with greater risk of clonal transmission (unadjusted P=0.34, adjusted P=0.18).

Conclusion

Intraoperative VISA is a rare event. S. aureus isolates MIC=2μg/mL isolates were not associated with increased risk of intraoperative transmission. The epidemiology of detected intraoperative transmission is consistent with Centers for Disease Control guidelines.

SUBMITTER: Hadder B

PROVIDER: S-EPMC9523349 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Molecular characterisation and epidemiology of transmission of intraoperative <i>Staphylococcus aureus</i> isolates stratified by vancomycin minimum inhibitory concentration (MIC).

Hadder Brent B Dexter Franklin F Robinson Alysha D M ADM Loftus Randy W RW

Infection prevention in practice 20220908 4

<h4>Background</h4>Reduced vancomycin susceptibility in <i>Staphylococcus aureus</i> (<i>S. aureus</i>) is considered a more pathogenic strain characteristic and is associated with treatment failure. We aimed to characterise the epidemiology of intraoperative transmission of <i>S. aureus</i> isolates with reduced vancomycin susceptibility.<h4>Methods</h4><i>S. aureus</i> isolates (N=173) collected from 274 randomly selected operating room environments at three major academic medical centres in 2 ...[more]

PMID: 36188333

Similar Datasets

Project description:IntroductionProsthetic joint infections (PJIs) are disastrous complications for patients and costly for healthcare organisations. They may promote bacterial resistance due to the extensive antibiotic use necessary in the PJI treatment. The PJI incidence is estimated to be 1%-3%, but the absolute numbers worldwide are high and increasing as large joint arthroplasties are performed by the millions each year. Current treatment algorithms, based on implant preserving surgery or full revision followed by a semitailored antibiotic regimen for no less than 2-3 months, lead to infection resolution in approximately 60% and 90%, respectively. Antibiotic choice is currently guided by minimum inhibitory concentrations (MICs) of free-living bacteria and not of bacteria in biofilm growth mode. Biofilm assays with relatively rapid output for the determination of minimum biofilm eradication concentrations (MBECs) have previously been developed but their clinical usefulness have not been established.Methods and analysisThis single-blinded, two-arm randomised study of hip or knee staphylococcal PJI will evaluate 6-week standard of care (MIC guided), or an alternative antibiotic regimen according to an MBEC-guided-based decision algorithm. Sixty-four patients with a first-time PJI treated according to the debridement, antibiotics, and implant retention principle will be enrolled at a single tertiary orthopaedic centre (Sahlgrenska University Hospital). Patients will receive 14 days of standard parenteral antibiotics before entering the comparative study arms. The primary outcome measurement is the proportion of changes in antimicrobial regimen from first-line treatment dependent on randomisation arm. Secondary endpoints are unresolved infection, how microbial properties including biofilm abilities and emerging antimicrobial resistance correlate to infection outcomes, patient reported outcomes and costs with a 12-month follow-up.Ethics and disseminationApproval is received from the Swedish Ethical Review Authority, no 2020-01471 and the Swedish Medical Products Agency, EudraCT, no 2020-003444-80.Trial registration numberClinicalTrials.gov ID: NCT04488458.